Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDX-1401
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MDX-1401 is a fully human, second-generation, nonfucosylated monoclonal antibody that targets the cell surface receptor CD30. It was developed to treat CD30-positive malignancies such as Hodgkin lymphoma. The lack of fucose in its structure increases its affinity for Fc gamma receptor IIIa (CD16) on immune effector cells, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) compared to earlier anti-CD30 antibodies. MDX-1401 has demonstrated preclinical and early clinical activity by reducing tumor burden and depleting circulating CD30-positive cells in patients with relapsed or refractory Hodgkin lymphoma. The drug was originally developed by Medarex and later by Bristol-Myers Squibb following their acquisition of Medarex[1][2][3][4][5][6].
- Other names
- anti-cd30 monoclonal antibody mdx-1401anti-cd-30 monoclonal antibody mdx-1401anti-cd 30 monoclonal antibody mdx-1401
02
Targets
CD30 (CD30 antigen)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on MDX-1401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDX-1401.